{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,2]],"date-time":"2025-09-02T10:46:48Z","timestamp":1756810008671},"reference-count":23,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2014,10,1]],"date-time":"2014-10-01T00:00:00Z","timestamp":1412121600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["heartfailure.theclinics.com","mdconsult.com","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heart Failure Clinics"],"published-print":{"date-parts":[[2014,10]]},"DOI":"10.1016\/j.hfc.2014.07.003","type":"journal-article","created":{"date-parts":[[2014,8,19]],"date-time":"2014-08-19T15:19:13Z","timestamp":1408461553000},"page":"559-564","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Mineralcorticoid Antagonists in Heart Failure"],"prefix":"10.1016","volume":"10","author":[{"given":"Emilia","family":"D\u2019Elia","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henry","family":"Krum","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.hfc.2014.07.003_bib1","doi-asserted-by":"crossref","first-page":"370","DOI":"10.7326\/0003-4819-101-3-370","article-title":"The neurohumoral axis in congestive heart failure","volume":"101","author":"Francis","year":"1984","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.hfc.2014.07.003_bib2","series-title":"Lo scompenso cardiaco","first-page":"25","article-title":"Fisiopatologia","author":"Gavazzi","year":"2002"},{"key":"10.1016\/j.hfc.2014.07.003_bib3","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/0002-9149(87)90468-1","article-title":"Autocrine\u2013paracrine mechanisms of vascular myocytes in hypertension","volume":"60","author":"Dzau","year":"1987","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.hfc.2014.07.003_bib4","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1161\/01.CIR.86.2.431","article-title":"Effects of angiotensin converting enzyme inhibitor, enalapril, on long-term progression of left ventricular dysfunction in patients with heart failure","volume":"86","author":"Konstam","year":"1992","journal-title":"Circulation"},{"key":"10.1016\/j.hfc.2014.07.003_bib5","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1161\/01.CIR.82.5.1730","article-title":"Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality","volume":"82","author":"Swedberg","year":"1990","journal-title":"Circulation"},{"issue":"Suppl VI","key":"10.1016\/j.hfc.2014.07.003_bib6","first-page":"VI-40","article-title":"Plasma norepinephrine, plasma renin activity, and congestive heart failure. Relations to survival and the effects of therapy in V-HeFT II. The V-HeFT VA Cooperative Studies Group","volume":"87","author":"Francis","year":"1993","journal-title":"Circulation"},{"issue":"Suppl A","key":"10.1016\/j.hfc.2014.07.003_bib7","doi-asserted-by":"crossref","first-page":"146A","DOI":"10.1016\/0735-1097(93)90480-O","article-title":"Comparative neurohormonal responses in patients with preserved and impaired left ventricular ejection fraction: results of the studies of left ventricular dysfunction (SOLVD) registry","volume":"22","author":"Benedict","year":"1993","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.hfc.2014.07.003_bib8","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1677\/joe.0.0910457","article-title":"Rise in plasma concentration of aldosterone during long-term angiotensin II suppression","volume":"91","author":"Staessen","year":"1981","journal-title":"J\u00a0Endocrinol"},{"key":"10.1016\/j.hfc.2014.07.003_bib9","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1002\/j.1552-4604.1993.tb03901.x","article-title":"Evidence of a partial escape of renin-angiotensin-aldosterone blockade in patients with acute myocardial infarction treated with ACE-inhibitors","volume":"33","author":"Borghi","year":"1993","journal-title":"J\u00a0Clin Pharmacol"},{"key":"10.1016\/j.hfc.2014.07.003_bib10","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1056\/NEJM198706043162301","article-title":"Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The CONSENSUS Trial Study Group","volume":"316","year":"1987","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.hfc.2014.07.003_bib11","first-page":"809","article-title":"Nuove evidenze sull\u2019impiego degli antialdosteronici nella disfunzione ventricolare sinistra: spironolattone ed eplerenone. Dal postinfarto allo scompenso cardiaco","volume":"13","author":"Greco","year":"2012","journal-title":"G\u00a0Ital Cardiol"},{"key":"10.1016\/j.hfc.2014.07.003_bib12","doi-asserted-by":"crossref","first-page":"2626","DOI":"10.1093\/eurheartj\/ehr170","article-title":"Mineralocorticoid receptor antagonism: therapeutic potential in acute heart failure syndromes","volume":"32","author":"Albaghdadi","year":"2011","journal-title":"Eur Heart J"},{"key":"10.1016\/j.hfc.2014.07.003_bib13","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1136\/hrt.2003.017368","article-title":"Effects of spironolactone on endothelial function, vascular angiotensin converting enzyme activity, and other prognostic markers in patients with mild heart failure already taking optimal treatment","volume":"90","author":"Macdonald","year":"2004","journal-title":"Heart"},{"key":"10.1016\/j.hfc.2014.07.003_bib14","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure","volume":"341","author":"Pitt","year":"1999","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.hfc.2014.07.003_bib15","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1093\/eurjhf\/hfn015","article-title":"on\u00a0behalf of AREA IN-CHF Investigators. Anti-remodeling effect of canrenone in patients with mild chronic heart failure (AREA IN-CHF study): final results","volume":"11","author":"Boccanelli","year":"2009","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.hfc.2014.07.003_bib16","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa030207","article-title":"Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction","volume":"348","author":"Pitt","year":"2003","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.hfc.2014.07.003_bib17","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1009492","article-title":"Eplerenone in patients with systolic heart failure and mild symptoms","volume":"364","author":"Zannad","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.hfc.2014.07.003_bib18","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1161\/CIRCHEARTFAILURE.112.000173","article-title":"Clinical benefit of eplerenone in patients with mild symptoms of systolic heart failure already receiving optimal best practice background drug therapy: analysis of the EMPHASIS-HF study","volume":"6","author":"Krum","year":"2013","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.hfc.2014.07.003_bib19","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1161\/CIRCULATIONAHA.112.110536","article-title":"Eplerenone in patients with systolic heart failure and mild symptoms: analysis of repeat hospitalizations","volume":"126","author":"Rogers","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.hfc.2014.07.003_bib20","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa1313731","article-title":"TOPCAT investigators. Spironolactone for heart failure with preserved ejection fraction","volume":"370","author":"Pitt","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.hfc.2014.07.003_bib21","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1093\/eurheartj\/eht187","article-title":"Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial","volume":"34","author":"Pitt","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.hfc.2014.07.003_bib22","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1161\/CIRCULATIONAHA.111.029892","article-title":"Effects of a novel aldosterone synthase inhibitor for treatment of primary hypertension: results of a randomized, double-blind, placebo- and active-controlled phase 2 trial","volume":"124","author":"Calhoun","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.hfc.2014.07.003_bib23","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1093\/eurheartj\/ehs104","article-title":"ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012","volume":"33","author":"McMurray","year":"2012","journal-title":"Eur Heart J"}],"container-title":["Heart Failure Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1551713614000580?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1551713614000580?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,30]],"date-time":"2018-09-30T12:52:50Z","timestamp":1538311970000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1551713614000580"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,10]]},"references-count":23,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2014,10]]}},"alternative-id":["S1551713614000580"],"URL":"https:\/\/doi.org\/10.1016\/j.hfc.2014.07.003","relation":{},"ISSN":["1551-7136"],"issn-type":[{"value":"1551-7136","type":"print"}],"subject":[],"published":{"date-parts":[[2014,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mineralcorticoid Antagonists in Heart Failure","name":"articletitle","label":"Article Title"},{"value":"Heart Failure Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hfc.2014.07.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}